Ketamine for OUD and Suicidal Ideation in the ED
This pilot, double-blind, placebo-controlled randomised clinical trial (n=50) led by Brigham and Women's Hospital assesses safety and preliminary efficacy of IV ketamine (0.8 mg/kg over 40 minutes) for individuals with opioid use disorder and suicidal ideation in the emergency department.
Details
Randomised, double-blind, placebo-controlled parallel-group trial of a single IV infusion of ketamine 0.8 mg/kg (over 40 minutes) versus matched saline in adults with moderate–severe opioid use disorder presenting to the ED with suicidal ideation.
Primary aim: safety of ketamine treatment in the ED; secondary aims: preliminary efficacy on opioid- and suicide-related outcomes. Safety assessments occur during and after infusion and at follow-up after discharge or inpatient psychiatric treatment.